• NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies. 

      Lau, Corinna; McAdam, MB; Bergseth, G; Grevys, Algirdas; Bruun, JA; Ludviksen, Judith K; Fure, Hilde; Espevik, Terje; Moen, A; Andersen, Jan Terje; Mollnes, Tom Eirik (Journal article; Peer reviewed, 2020)
      The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor ...